Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

A Multicenter, Open-Label Study of the Safety, Tolerability, and Immunogenicity of Revaccination With PNEUMOVAX(TM) 23 Vaccine (Pneumococcal Vaccine Polyvalent, Merck & Co., Inc.) in Older Adults

The purpose of this study is to determine that revaccination of Pneumococcal Vaccine is well tolerated and produces an immune response in older adults.

This study is an extension study (V110-007-10) which met requirements for posting on clinicaltrials.gov. The original study (V110-007-00) was completed in 2004 and did not meet the criteria for registration.

Inclusion Criteria:

• Postmenopausal or negative urine pregnancy test if female
• No fever on the day of vaccination

Exclusion Criteria:

• History of allergy to vaccine components
• History of pneumococcal disease
• Received any live virus vaccination within 4 weeks prior to study start
• Received any inactivated vaccination within 7 days prior to study start
• Received any blood products within 5 months prior to study start
• Participated in an investigational drug or vaccine study in the past 30 days
• Received immunosuppressive therapy
• Patient has an immune deficiency